A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir.

Remdesivir (RDV) is the first nucleoside analog drug approved by the FDA for COVID-19 therapy through intravenous administration, having positive clinical feedback for reduced recovery time but a nonsignificant trend toward lowering mortality. 4 – 6 Molnupiravir (EIDD-2801) is an oral prodrug of β-d-N4-hydroxycytidine (NHC) that can inhibit SARS-CoV-2 replication via nucleoside analog incorporation into viral RNA, inducing lethal accumulation of mutations in the viral genome.

also in 5,406 other papers